logo
SRT Is Back, But Is It Enough to Rev Stellantis Into the Near Future?

SRT Is Back, But Is It Enough to Rev Stellantis Into the Near Future?

Motor Trend3 days ago
You can argue the North American brands under Stellantis have been defanged in recent years. Under former Stellantis CEO Carlos Tavares' leadership, Ram trucks lost their V-8s, Jeep lost volume models and failed to launch promised new ones in a timely manner, Chrysler subsists today on minivans alone, and Dodge slow-walked the rollout of its new muscle cars.
Stellantis revives its Street and Racing Technology (SRT) division under new CEO Antonio Filosa and Tim Kuniskis, aiming to boost North American performance cars. SRT will unify Dodge, Ram, Jeep, and Chrysler's high-performance efforts, promising a wave of powerful vehicles.
This summary was generated by AI using content from this MotorTrend article. Read Next The New Order
Now there's a new sheriff in town, as Antonio Filosa, a man more sympathetic to North American demands, is the new CEO. And Stellantis brought back retired Tim Kuniskis, a man with petrol and adrenaline comingled in his veins and who had apparently ridden off into the sunset not long ago, in June 2024.
With the personnel moves came a series of quick announcements: Hellcat godfather and Ram CEO Kuniskis was promoted to spread his enthusiasm and supercharge all American products; he is now head of American brands and North America marketing and retail strategy for Stellantis while retaining his role as Ram CEO.
Under his guidance, the 2026 Ram 1500 can now be ordered with the 5.7-liter Hemi V-8 as an option, but the bigger-picture news is that Stellantis is bringing back the Street and Racing Technology (SRT) division to unify high-performance efforts at Dodge, Ram, Jeep, and Chrysler. Kuniskis will run this, too.
SRT's revival is guaranteed to crank the driveshafts of performance junkies and Mopar faithful alike. It means factory-built horsepower and street- and track-engineering prowess. Bringing back SRT is designed to jumpstart the revitalization of the North American products and restore Stellantis' vitality in the region where sales, market share, and profits have fallen, trust has been lost, and morale has eroded.
'We're getting the band back together,' Kuniskis said of resurrecting the vaunted SRT division, which was dissolved in 2021 and its engineers scattered. 'SRT is another box we needed to check as we head into a product launch cadence enabling more performance than we've ever seen before.'
SRT will also oversee Direct Connection—Dodge's performance parts and tuning division—which means its tuner catalog and racing involvement are poised to expand. Also under the SRT umbrella are the North American motorsports programs, which include Dodge's NHRA drag racing team and Ram's return to the NASCAR Truck Series in 2026. Ram has already shown a Ram 1500 concept race truck with an engine revving to more than 9,000 rpm. SRT Evolution
SRT has been a prominent in-house skunkworks of sorts since 1989, existing under a number of different names. It began with the Specialty Vehicle Engineering (SVE) team that brought the original Dodge Viper to life and helped create the Plymouth Prowler, two reasons why SRT has always been synonymous with the boldest, most memorable Mopar vehicles in recent years.
Chrysler formed the Performance Vehicle Operations high-performance division in 2004. From the ashes of PVO came the SRT division, which was elevated to official brand status in 2011. Design chief Ralph Gilles at the time added SRT CEO to his duties, an extra task he relished for four years.
SRT was relegated back to a development team in 2014. Then it was quietly phased out as Stellantis consolidated brand operations, dissolving SRT in 2021 but redistributing its engineers and mandates to the parent company's individual brands to continue their work there. Fruits of their labor included the Jeep Grand Cherokee Trackhawk and 2021 Ram 1500 TRX. SRT is Back, Baby
SRT's return signals a bold recommitment to enthusiast culture at a time when electrification, regulatory pressures, and platform sharing have clouded the future of internal combustion performance. Expect to see a product wave of performance vehicles with an assortment of drivetrains to rival or surpass the Hellcat era in scale and scope. The history of SRT and Hellcat has always been 'go big or go home,' the more outrageous the better.
This should result in off-road monsters for Jeep and Ram, dragstrip-bruising muscle sedans and coupes for Dodge, and gentrified premium power for Chrysler.
There are many vehicles the revived SRT can tap for inspiration. It could begin with the Viper, a wild V-10-powered sports car first shown as a concept in 1989 at the North American International Auto Show in Detroit. It went into production in 1992 and was discontinued in 2017 when it could not meet modern side-curtain airbag regulations. Before it died, Dodge added the much-revered Viper ACR track special. Even in the electric age, it would be cool to see a V-10-powered snake again, but we won't hold our breath on this one.
At the other end of the spectrum was the 2003 Dodge Neon SRT-4, a cute compact car with a turbocharged engine that offered excellent handling, cheap speed, and riotous (or heinous, depending on your point of view) torque steer.
For curbside cool, there was the 2006 Dodge Magnum SRT-8 wagon. Sure, it had siblings (the Charger SRT8 and Challenger SRT8) with the same 425-hp 6.1-liter Hemi V-8, but the Magnum roamed the streets in a menacing way unlike anything else on the market during its short life from 2006 to '08.
Meanwhile, the 2004 Dodge Ram SRT-10 had the Viper's V-10 stuffed under its hood plus a manual transmission. This is the kind of crazy fun Kuniskis should try to bring back, even if the transmission goes automatic. The Ram 1500 TRX needs a successor.
A more practical SRT was the hot-rodded 2006 Jeep Grand Cherokee SRT8, which took a relatively conventional SUV and dialed it into the realm of absurd during the SUV's third generation. Its successor? The 2018 Jeep Grand Cherokee Trackhawk with a fully independent suspension and a 707-hp 6.2-liter supercharged Hellcat V-8.
The vehicle that cemented Kuniskis' reputation: the 2023 Dodge Challenger SRT Demon 170. This dragstrip special boasted a Hellcat V-8 tuned to run on E85 ethanol fuel and a big supercharger for an unhinged but street-legal 1,025 hp and 945 lb-ft of torque.
Our wish list for the new SRT? Today the only vehicle bearing the name is the aging Dodge Durango SRT Hellcat. Fresh lineup additions could and should include a lowered Ram 1500 SRT street truck with a Hemi V-8 to take on the Ford F-150 Lobo. Ram so far is only bringing back the 5.7-liter and says it would be a lot of work to incorporate the 6.2-liter engine into the electrical architecture in today's trucks, but that doesn't sound like the kind of problem that stopped Kuniskis before. Dodge is also working on a powerful electric Charger Daytona Banshee, so we're surely not alone in hoping Gilles designs a new Magnum on the STLA Large platform, with a V-8.
The Grand Cherokee seems ripe for a new performance variant, too. A V-8 won't fit, but you have to think engineers can squeeze more out of the excellent 3.0-liter twin-turbo Hurricane inline-six.
And thinking more about the Viper, at least in name: Maserati has some high-end sports car platforms. Maybe SRT might marry some of those mechanicals with some American muscle? The name alone would likely fuel big interest, and Stellantis as a whole could certainly use the win.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

China welcomes 183 Brazil coffee sellers in wake of US tariffs
China welcomes 183 Brazil coffee sellers in wake of US tariffs

Yahoo

time4 minutes ago

  • Yahoo

China welcomes 183 Brazil coffee sellers in wake of US tariffs

By Ana Mano SAO PAULO (Reuters) -China has approved 183 new Brazilian coffee companies to export products to the Chinese market, according to a social media post of the Chinese embassy in Brazil on Saturday. The measure, a boon to local exporters after the United States government's announcement of steep tariffs on Brazilian coffee and other products, took effect on July 30. The new Chinese export permits are valid for five years, according to the post. The U.S.'s 50% tariff on some Brazilian products will begin on August 6. The levy represents a challenge for commodities traders and Brazilian coffee exporters, who need to find alternatives for the roughly 8 million bags sold to U.S. coffee processors every year. China is Brazil's top trade partner overall while the U.S. is a big buyer of Brazilian beef and orange juice, among other products. In June, Brazilian coffee exports into the U.S. totaled 440,034 60-kilo bags, 7,87 times more than Brazil's sales into China of nearly 56,000 bags that month, according to trade data compiled by industry lobby Cecafe. The Brazilian ministry of agriculture and Cecafe did not have an immediate comment. China's customs authority could not be immediately reached as it was outside the business hours. Brazil supplies about a third of the U.S. coffee demand each year, a trade valued at $4.4 billion in the 12 months ended in June. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Ball (NYSE:BALL) Will Pay A Dividend Of $0.20
Ball (NYSE:BALL) Will Pay A Dividend Of $0.20

Yahoo

time4 minutes ago

  • Yahoo

Ball (NYSE:BALL) Will Pay A Dividend Of $0.20

The board of Ball Corporation (NYSE:BALL) has announced that it will pay a dividend of $0.20 per share on the 16th of September. Including this payment, the dividend yield on the stock will be 1.4%, which is a modest boost for shareholders' returns. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Ball's Projected Earnings Seem Likely To Cover Future Distributions The dividend yield is a little bit low, but sustainability of the payments is also an important part of evaluating an income stock. Prior to this announcement, Ball was quite comfortably covering its dividend with earnings and it was paying more than 75% of its free cash flow to shareholders. The company is clearly earning enough to pay this type of dividend, but it is definitely focused on returning cash to shareholders, rather than growing the business. Looking forward, earnings per share is forecast to rise by 135.1% over the next year. Assuming the dividend continues along recent trends, we think the payout ratio could be 20% by next year, which is in a pretty sustainable range. Check out our latest analysis for Ball Ball Has A Solid Track Record Even over a long history of paying dividends, the company's distributions have been remarkably stable. The annual payment during the last 10 years was $0.26 in 2015, and the most recent fiscal year payment was $0.80. This means that it has been growing its distributions at 12% per annum over that time. We can see that payments have shown some very nice upward momentum without faltering, which provides some reassurance that future payments will also be reliable. Ball Could Grow Its Dividend Investors could be attracted to the stock based on the quality of its payment history. Ball has seen EPS rising for the last five years, at 5.8% per annum. Shareholders are getting plenty of the earnings returned to them, which combined with strong growth makes this quite appealing. Our Thoughts On Ball's Dividend Overall, it's nice to see a consistent dividend payment, but we think that longer term, the current level of payment might be unsustainable. While Ball is earning enough to cover the dividend, we are generally unimpressed with its future prospects. We would be a touch cautious of relying on this stock primarily for the dividend income. It's important to note that companies having a consistent dividend policy will generate greater investor confidence than those having an erratic one. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. Case in point: We've spotted 2 warning signs for Ball (of which 1 shouldn't be ignored!) you should know about. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

With 65% institutional ownership, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a favorite amongst the big guns
With 65% institutional ownership, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a favorite amongst the big guns

Yahoo

time4 minutes ago

  • Yahoo

With 65% institutional ownership, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a favorite amongst the big guns

Key Insights Given the large stake in the stock by institutions, Rigel Pharmaceuticals' stock price might be vulnerable to their trading decisions 51% of the business is held by the top 9 shareholders Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To get a sense of who is truly in control of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), it is important to understand the ownership structure of the business. With 65% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's take a closer look to see what the different types of shareholders can tell us about Rigel Pharmaceuticals. Check out our latest analysis for Rigel Pharmaceuticals What Does The Institutional Ownership Tell Us About Rigel Pharmaceuticals? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Rigel Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Rigel Pharmaceuticals' earnings history below. Of course, the future is what really matters. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It would appear that 15% of Rigel Pharmaceuticals shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Our data shows that BlackRock, Inc. is the largest shareholder with 9.7% of shares outstanding. Armistice Capital LLC is the second largest shareholder owning 8.5% of common stock, and Morgan Stanley, Investment Banking and Brokerage Investments holds about 8.3% of the company stock. Furthermore, CEO Raul Rodriguez is the owner of 0.8% of the company's shares. We did some more digging and found that 9 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. Insider Ownership Of Rigel Pharmaceuticals While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Shareholders would probably be interested to learn that insiders own shares in Rigel Pharmaceuticals, Inc.. As individuals, the insiders collectively own US$5.5m worth of the US$392m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling. General Public Ownership With a 19% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Rigel Pharmaceuticals. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Rigel Pharmaceuticals better, we need to consider many other factors. For example, we've discovered 1 warning sign for Rigel Pharmaceuticals that you should be aware of before investing here. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store